Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
详细信息 查看全文
- 作者：Alice Levard (1)
Olfa Derbel (1)
Pierre Méeus (2)
Dominique Ranchère (3)
Isabelle Ray-Coquard (1)
Jean-Yves Blay (1)
Philippe A Cassier (1) (4) - 刊名：BMC Cancer
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：232KB
- 参考文献：1. Fletcher CD: The evolving classification of soft tissue tumours: an update based on the new WHO classification. / Histopathology 2006, 48:3-2. CrossRef
2. Gengler C, Guillou L: Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. / Histopathology 2006, 48:63-4. CrossRef
3. Brunnemann RB, Ro JY, Ordonez NG, Mooney J, el-Naggar AK, Ayala AG: Extrapleural solitary fibrous tumor: a clinicopathologic study of 24 cases. / Mod Pathol 1999, 12:1034-042.
4. Park MS, Araujo DM: New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. / Curr Opin Oncol 2009, 21:327-31. CrossRef
5. Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ: Clinicopathologic correlates of solitary fibrous tumors. / Cancer 2002, 94:1057-068. CrossRef
6. England DM, Hochholzer L, McCarthy MJ: Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. / Am J Surg Pathol 1989, 13:640-58. CrossRef
7. Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW: Hemangiopericytoma: a 20-year single-institution experience. / Ann Surg Oncol 1998, 5:350-55. CrossRef
8. Magdeleinat P, Alifano M, Petino A, Le Rochais JP, Dulmet E, Galateau F: Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. / Eur J Cardiothorac Surg 2002, 21:1087-093. CrossRef
9. Constantinidou A, Jones RL, Olmos D, Thway K, Fisher C, Al-Muderis O: Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. / Acta Oncol 2012, 51:550-54. CrossRef
10. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG: Management of recurrent meningeal hemangiopericytoma. / Cancer 1998, 82:1915-920. CrossRef
11. Chaigneau L, Kalbacher E, Thiery-Vuillemin A, Fagnoni-Legat C, Isambert N, Aherfi L: Efficacy of trabectedin in metastatic solitary fibrous tumor. / Rare Tumors 2011, 3:e29. CrossRef
12. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. / J Clin Oncol 2007, 25:1753-759. CrossRef
13. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ: Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. / Cancer 2011, 117:4939-947. CrossRef
14. Domont J, Massard C, Lassau N, Armand JP, Le CA, Soria JC: Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. / Invest New Drugs 2010, 28:199-02. CrossRef
15. de IC-M, Grande-Pulido E, bero-Tamarit A, de Villena ME C-M: Cancer and immune response: old and new evidence for future challenges. / Oncologist 2008, 13:1246-254. CrossRef
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. / J Natl Cancer Inst 2000, 92:205-16. CrossRef
17. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De TB: Sunitinib malate in solitary fibrous tumor (SFT). / Ann Oncol 2012, 23:3171-179. CrossRef
18. George S, Blay JY, Casali PG, Le CA, Stephenson P, DePrimo SE: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. / Eur J Cancer 2009, 45:1959-968. CrossRef
19. Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. / Curr Opin Oncol 2010, 22:351-55. CrossRef
20. Chevreau C, Le Cesne A, Ray-Coquard I, Bui Nguyen B, Bompas E, Isambert N: Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT). / J Clin Oncol (Meeting Abstracts) 2012, 30:10020.
21. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/109/prepub - 作者单位：Alice Levard (1)
Olfa Derbel (1)
Pierre Méeus (2)
Dominique Ranchère (3)
Isabelle Ray-Coquard (1)
Jean-Yves Blay (1)
Philippe A Cassier (1) (4)
1. Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
2. Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
3. Department of Anatomopathology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France
4. Department of Medical Oncology, Centre Léon Bérard, Lyon, France - ISSN：1471-2407
文摘
Background Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient. Methods We conducted a retrospective study on patients treated for advanced SFT at a single institution: from January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT. Results Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%) partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2nd, 3rd or 4th line. Best responses were 5 SD and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two patients receiving sunitinib were free of progression at 30 months. Conclusion Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic chemotherapy and anti-angiogenic agents.